Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor

Journal of Neuro-Oncology

Volumn 56, Issue 3, 2002, Pages 219-226

  Morales, C ^a   Zurita, M ^a   Vaquero, Jesús ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Brain neoplasms; CPT 11; Experimental tumor; Intratumoral chemotherapy; Osmotic minipump

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL MODEL; HISTOPATHOLOGY; NERVOUS SYSTEM TUMOR; NEUROECTODERM TUMOR; NONHUMAN; OSMOTIC MINIPUMP; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; CAMPTOTHECIN; CELL DIVISION; NEUROECTODERMAL TUMORS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0036255614     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015014623569     Document Type: Article

References (46)

1. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
2. The current status of camptothecin analogues as antitumor agents
3. Camptothecins: From bench research to hospital wards
4. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
5. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
6. DNA topoisomerases
7. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complex as a mechanism of cell killing by camptothecin
8. Synthesis of water soluble (aminoalkyl) camptothecin analoges: Inhibition of topoisomerase I and antitumor activity
9. Preclinical evaluation of CPT-11 and its active metabolite SN-38
10. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
11. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice
12. Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice
13. Irinotecan (CPT-11): Current status and perspectives
14. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
15. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma
16. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
17. Clinical studies of irinotecan alone and in combination with cisplantin
18. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group
19. Multicentric phase II study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRP): Preliminary results
20. Irinotecan (CPT-11) as second-line therapy for patients with 5-FU-refractory colorectal cancer
21. Phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study
22. Therapeutic efficacy of topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino)-1-piperidino)-carbonyloxy-camtothecin against pediatric and adult central nervous system tumor xenografts
23. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents
24. Treatment of CNS xenografts with camptothecins
25. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xenotransplanted neuroblastoma
26. DNA-topoisomerase I, a new target for the treatment of neuroblastoma
27. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
28. Irinotecan therapy in adults with recurrent or progressive malignant glioma
29. Interstitial chemotherapy for brain tumors: Review
30. Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model
31. Experimental induction of primitive neuroectodermal tumors in rats: A reapraisement of the ENU-model of neurocarcinogenesis
32. Intratumoral chemotherapy
33. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implantation in camptothecin activity
34. Local delivery of topoisomerase inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model
35. Topoisomerase enzymes as drug target
36. Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm
37. Induction of apoptosis in MDR human glioblastoma cells by SN-38, a metabolite of CPT-11
38. Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways
39. Antiangiogenic potential of camptothecin and topotecan
40. Antiangiogenic effects of camptothecin analoges 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
41. Topoisomerase I inhibitor with potential radiosensitizing effect
42. DNA topoisomerase I-targeting drugs as radiation sensitizers
43. Interaction of ionizing with topotecan in two human cell lines
44. Effects of SN-38 (an active metabolite of CPT-11) on responses of human and rodent cells to irradiation
45. Camptothecin radiation sensitization: Mechanisms, schedules and timing
46. DNA topoisomerase I-targeting drugs as radiation sensitizer